Table 2.

Comparison of clinicopathological features between KRAS mutation positive and negative invasive mucinous adenocarcinoma cases (n = 47)

Clinicopathological characteristics	KRAS mutation status		p value
	Positive (n = 25)	Negative (n = 22)
Age, years
Median (range)	71.0 (45–86)	70.5 (59–81)	0.349
Interquartile range	62.5–75.5	65.0–76.3
Sex, n (%)
Male	10 (40.0)	13 (59.1)	0.311
Female	15 (60.0)	9 (40.9)
Smoking status, n (%)
Never smoker	15 (60.0)	9 (40.9)	0.311
Ex- or current smoker	10 (40.0)	13 (59.9)
Radiological feature, n (%)
Solitary	16 (64.0)	16 (72.3)	0.744
Pneumonic	9 (36.0)	6 (27.3)
Surgical procedure, n (%)
Pneumonectomy	0 (0.0)	1 (4.6)	0.948
Lobectomy	21 (84.0)	17 (77.2)	0.831
Segmentectomy	4 (16.0)	3 (13.6)	0.854
Wedge resection	0 (0.0)	1 (4.6)	0.948
Genetic variant status, n (%)
EGFR mutation	2 (8.7)	0 (0.0)	0.489
BRAF mutation	0 (0.0)	1 (4.5)	0.982
NRG1 fusion	2 (8.7)	1 (4.5)	0.968
Wild type	19 (82.6)	20 (91.0)	0.704
Immunoreactivity, n (%)
TTF-1*
Negative	18 (80.1)	18 (19.2)	0.941
Positive/focally positive	3 (9.5)/2 (9.5)	2 (12.5)/2 (8.3)
PD-L1*
Negative	23 (100)	20 (90.9)	0.450
Positive	0 (0.0)	2 (9.1)
Lymphovascular invasion, n (%)
Negative	23 (92.0)	20 (91.0)	0.696
Positive	2 (8.0)	2 (9.0)
Nodal metastasis, n (%)
Negative	24 (96.0)	21 (95.8)	0.528
Positive	1 (4.0)	1 (4.2)
pStage, n (%)
IA1/IA2/IA3	11 (44.0)	13 (59.1)	0.301
IB	3 (12.0)	4 (18.2)	0.854
IIA/IIB	9 (36.0)	4 (18.2)	0.300
IIIA	2 (8.0)	1 (4.5)	0.909
Recurrence, n (%)
Negative	15 (60.0)	19 (82.4)	0.091
Positive	10 (40.0)	3 (13.6)

AIS adenocarcinoma in situ, MIA minimally invasive adenocarcinoma, SUV standard uptake value

*Estimated among 54 available cases